TGFB1 and diabetic kidney disease: Animal studies have shown that isoflavone administration delays the progression of diabetic nephropathy, fibrosis, and renal inflammation through activation of the Nrf2 antioxidant pathway and inhibition of profibrotic and proinflammatory signals such as TGF-β and NF-κB.